Pfizer Backs EU Manufacturing With €2.4bn Investment
Ireland And Belgium To Benefit
Pfizer is betting big on its manufacturing plans in Europe, investing €1.2bn at respective sites in Ireland and Belgium to prepare for a number of launches it has lined up in the short term.
You may also be interested in...
Excluding the multinational majors AstraZeneca and GSK, the UK has yet to produce a truly successful scaled pharma company, despite having boasted several innovative start-ups. Whether that represents a negative, however, is a matter for debate.
The pipeline to treat the neurological disorder, which is characterized by uncontrolled rapid and repeated movements or sounds, is very thin but a couple of biotechs either side of the Atlantic are making progress.
The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.